SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.97% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.45%, a 235.62% increase from fiscal 2021.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.73%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.97% 10-Q · filed 2026-09-24 | |||
| 2022-12-31 | 2.45% 10-K · filed 2023-03-15 | |||
| 2022-08-31 | 3.43% 10-K/A · filed 2024-09-04 | |||
| 2022-08-01 | 2.66% 10-K/A · filed 2024-09-04 | |||
| 2022-04-30 | 2.55% 10-K/A · filed 2024-09-04 | |||
| 2021-12-31 | 0.73% 10-K · filed 2023-03-15 | |||
| 2021-12-28 | 1.27% 10-K/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |